Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesInnate Pharma

Innate Pharma

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
1.59 USD 0.05 ( 3.25%)
Last update at 2026-11-11T21:00:00Z
VOLUME
7495
Market Cap
235.13M

Momentum Score

…

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.53
Low
1.61
High
52 Week Price Range
1.81
Low
3.57
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Innate Pharma is a clinical-stage biopharmaceutical company developing monoclonal antibodies that modulate the innate immune system, with a focus on natural killer cell checkpoints. Long-term growth may be driven by clinical trial progress, regulatory milestones and partnerships that could support development and commercialization; its pipeline and collaborations may appeal to investors seeking exposure to novel immuno-oncology approaches. Principal risks include high clinical and regulatory uncertainty, reliance on successful trial outcomes and partner funding, ongoing financing needs for development, and intense competition in oncology therapeutics.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
1.54
Dividend Yield
-
Revenue TTM
61.64M
Revenue Per Share
0.77
Gross Profit TTM
57.67M
Debt / Equity
0.77
ROE
-14.28%
Net Debt
-30.71M
ROCE
-8.06%
Diluted EPS TTM
-0.10

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -57.97M -45.48M -63.98M -20.76M 2.72M
Minority interest - - - 0.00M 0.00M
Net income -99.10M -59.14M -70.75M -20.96M 3.05M
Selling general administrative 14.47M 15.99M 31.25M 40.73M 18.14M
Selling and marketing expenses 7.96M 9.53M -0.86M 8.85M 1.11M
Gross profit 49.64M 12.11M 53.79M 23.82M 79.89M
Reconciled depreciation 45.41M 4.60M 56.80M 16.53M 7.40M
Ebit -11.65M -47.83M -13.69M -27.05M 4.96M
Ebitda 33.75M -36.88M 43.10M -8.88M 12.36M
Depreciation and amortization 45.41M 10.94M 56.80M 18.17M 7.40M
Non operating income net other - - - 0.00M 0.00M
Operating income -11.65M -47.83M -13.69M -27.05M 5.15M
Other operating expenses 66.06M 59.94M 75.38M 96.03M 74.75M
Interest expense 5.32M 4.00M 6.76M 0.20M 0.10M
Tax provision 0.00M 0.00M 0.00M 0.00M -0.33M
Interest income 4.78M 6.34M 4.86M 1.62M -
Net interest income -0.55M 2.35M -1.91M 1.43M -0.28M
Extraordinary items - - - 0.00M 0.00M
Non recurring - - - 0.00M 0.00M
Other items - - - 0.00M 0.00M
Income tax expense 41.13M 13.66M 6.76M 0.21M -0.33M
Total revenue 49.64M 12.11M 56.83M 68.97M 79.89M
Total operating expenses 66.06M 59.94M 75.38M 50.87M 74.75M
Cost of revenue - - 3.04M 45.16M 360.85M
Total other income expense net -46.32M 2.35M -50.29M 6.29M -2.14M
Discontinued operations -0.13M -7.33M -7.33M -7.33M -7.33M
Net income from continuing ops -57.97M -45.48M -63.98M -20.76M 3.05M
Net income applicable to common shares -58.10M -52.81M -63.98M -20.76M 3.05M
Preferred stock and other adjustments - - - 0.00M 0.00M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 184.19M 207.86M 267.50M 307.42M 401.36M
Intangible assets 0.42M 42.55M 44.19M 46.29M 96.97M
Other current assets 9.07M 0.00M 21.81M 18.74M -0.00M
Total liab 132.29M 153.71M 160.06M 151.45M 183.94M
Total stockholder equity 51.90M 54.15M 107.44M 155.97M 217.42M
Deferred long term liab - - - - 0.00M
Other current liab 16.27M 11.77M 8.06M 2.51M 42.99M
Common stock 4.04M 4.01M 3.98M 3.95M 3.94M
Capital stock 4.04M 4.01M 3.98M 3.95M 3.94M
Retained earnings -336.89M -330.32M -272.21M -220.46M -155.67M
Other liab - 72.22M 66.67M 87.81M 45.53M
Good will - -41.00M 0.00M 0.00M 0.00M
Other assets - -0.00M -0.00M 37.17M 18.11M
Cash 70.61M 84.22M 103.76M 136.79M 202.89M
Total current liabilities 39.64M 41.34M 79.89M 46.69M 121.82M
Current deferred revenue 5.87M 6.56M 12.50M 12.51M 48.77M
Net debt -30.71M -41.97M -59.51M -117.70M -184.16M
Short term debt 8.94M 2.10M 30.75M 2.14M 2.13M
Short long term debt 8.45M 1.26M 30.75M 2.14M 1.49M
Short long term debt total 39.89M 42.25M 44.25M 19.09M 18.72M
Other stockholder equity 384.26M 379.64M 375.22M 372.13M 369.62M
Property plant equipment - 8.54M 10.17M 11.69M 11.67M
Total current assets 148.01M 139.83M 138.26M 173.33M 237.60M
Long term investments 9.80M 35.12M 39.88M 38.93M 37.01M
Net tangible assets - 52.59M 63.25M 109.69M 120.45M
Short term investments 21.85M 17.26M 16.08M 14.85M 15.98M
Net receivables 46.49M 38.35M 18.42M 21.70M 13.14M
Long term debt 30.61M 38.93M 13.50M 16.95M 14.10M
Inventory 0.00M -0.00M -21.81M -18.74M 5.60M
Accounts payable 8.56M 20.91M 28.57M 29.54M 27.94M
Total permanent equity - - - - 0.00M
Noncontrolling interest in consolidated entity - - - - 0.00M
Temporary equity redeemable noncontrolling interests - - - - 0.00M
Accumulated other comprehensive income 0.49M 0.82M 0.46M 0.35M -0.47M
Additional paid in capital - - - - 0.00M
Common stock total equity - - - 3.95M 3.94M
Preferred stock total equity - - - - 0.00M
Retained earnings total equity - - - - 0.00M
Treasury stock - - - - 0.00M
Accumulated amortization - - - - 0.00M
Non currrent assets other 10.64M 14.25M 29.97M 30.09M 16.83M
Deferred long term asset charges - - - - 0.00M
Non current assets total 36.18M 68.03M 129.24M 134.09M 163.76M
Capital lease obligations 0.83M 2.06M 2.82M 3.53M 3.13M
Long term debt total - - - - 0.00M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 1.88M -0.92M -13.37M -62.12M 24.28M
Change to liabilities 0.00M -7.01M -51.67M -59.70M 83.60M
Total cashflows from investing activities 1.88M -0.92M -13.37M -62.12M 24.28M
Net borrowings -2.03M 26.63M -0.84M 11.92M -1.34M
Total cash from financing activities -1.83M 26.82M -1.14M 77.77M 61.22M
Change to operating activities -12.50M -9.88M -49.20M -10.35M -13.10M
Net income -58.10M -52.81M -63.98M -20.76M 3.05M
Change in cash -19.53M -33.04M -66.09M 50.57M 52.95M
Begin period cash flow 103.76M 136.79M 202.89M 152.31M 99.37M
End period cash flow 84.22M 103.76M 136.79M 202.89M 152.31M
Total cash from operating activities -19.15M -58.46M -51.81M 34.92M -32.53M
Issuance of capital stock - 0.00M 0.00M 66.01M 62.56M
Depreciation 45.41M 4.60M 56.80M 16.53M 7.40M
Other cashflows from investing activities -0.00M 0.41M 0.90M 1.28M 1.47M
Dividends paid 0.00M 0.00M 0.00M 0.00M 0.00M
Change to inventory - -6.27M 25.38M 0.00M 0.00M
Change to account receivables -4.20M 3.39M -22.92M 110.30M -678.07M
Sale purchase of stock - - - 0.00M 0.00M
Other cashflows from financing activities 0.20M 28.89M 1.07M 13.74M 0.01M
Change to netincome 6.05M -0.36M 4.58M -1.09M 4.18M
Capital expenditures 1.12M 1.33M 11.28M 65.40M 1.43M
Change receivables - - - 0.00M 0.00M
Cash flows other operating - - - 0.00M 0.00M
Exchange rate changes - - - 0.00M 0.00M
Cash and cash equivalents changes - - - 0.00M 0.00M
Change in working capital -12.50M -9.88M -49.20M 40.25M -47.10M
Stock based compensation 4.25M 2.62M 2.48M 3.83M 2.71M
Other non cash items 1.80M -1.29M -0.54M -0.77M 0.25M
Free cash flow -20.28M -59.79M -63.09M -30.48M -33.96M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
IPHA
Innate Pharma		 0.05
3.25%		 1.59 - - 3.26 3.62 2.81 -79.44
NVO
Novo Nordisk A/S		 0.41
1.00%		 41.10 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -0.86
0.16%		 547.03 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 43.35
4.73%		 959.41 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Innate Pharma

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

117, Avenue de Luminy, Marseille, France, 13009

33 4 30 30 30 30

https://www.innate-pharma.com

179

Name Title Year Born
Dr. Mondher Mahjoubi M.D. Chairman of Exec. Board & CEO 1958
Mr. Yannis Morel Ph.D. Exec. VP of Product Portfolio Strategy & Bus. Devel. and Member of Exec. Board 1973
Dr. Herve Brailly Co-Founder & Chairman of Supervisory Board 1961
Dr. François Romagné Ph.D. Founder 1964
Mr. Eric Vivier D.V.M., M.B.A., Ph.D. Founder, Sr. VP & Chief Scientific Officer 1964
Dr. Marc Bonneville Ph.D. Founder 1960
Mr. Jean Jacques Fournié Ph.D. Founder NA
Mr. Alessandro Moretta M.D., Ph.D. Founder NA
Mr. Frederic Lombard M.B.A. Sr. VP & CFO 1975
Ms. Odile Belzunce VP of Compliance & Operations 1980

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

MAL
CAD 38.85
+13.53%
SOIL
CAD 8.39
+12.02%
QNC
CAD 1.48
+10.45%
TCL-B
CAD 7.26
+9.01%
CLS
CAD 345.53
+8.41%
GSY
CAD 37.75
-16.04%
BYD
CAD 109.98
-11.99%
ELE
CAD 20.12
-11.95%
LAC
CAD 2.39
-11.15%
CFW
CAD 6.51
-10.82%

Equity Sectors*

  • Basic Materials

    -1.75%

  • Communication Services

    +0.20%

  • Consumer Cyclical

    +0.18%

  • Consumer Defensive

    +0.06%

  • Energy

    +1.65%

  • Financial Services

    +0.10%

  • Healthcare

    +1.25%

  • Industrials

    +1.60%

  • Real Estate

    -0.29%

  • Technology

    +2.72%

  • Utilities

    +0.12%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…